Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

3月1日，江北新区南京生物医药谷园区企业北恒生物宣布，其靶向CD7的通用型CAR-T细胞疗法CTD402已获得美国食品药品监督管理局（FDA）的新药临床试验申请（IND）批准，用于治疗复发/难治性T细胞急性淋巴细胞白血病/淋巴瘤（R/R T-ALL/LBL）的儿童及成人患者。FDA批准的这项研究是一项单臂、开放标签的Ib/II期临床试验，采用简化的剂量探索设计，旨在优化给药方案并加速临床开发进程。

图 1：研究截图 在该研究中，陆佩华院长带领团队创新性地采用基于纳米抗体的 CD7 CAR-T 治疗 AML，研究结果不仅在肿瘤杀伤力和安全性上取得了显著 ...

Bioheng Therapeutics US LLC has obtained IND approval from the FDA for CTD-402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with relapsed or ...

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

Researchers found that naturally-occurring CD7-negative T cells avoid self-destruction and are good effectors in CAR T therapy for T cell blood cancers. Deanna earned their PhD in cellular biology ...

Bioheng Therapeutics’ IND application for CTD402 gets US FDA clearance for CD7 UCAR T cell therapy in T-cell acute lymphoblastic leukemia: Boston Friday, March 7, 2025, 16:00 Hr ...

CTD402 is a universal CAR-T cell product targeting CD7 derived from healthy donors and intended for the treatment of T-ALL/LBL. It is genetically modified to avoid fratricide, graft-versus-host ...

CTD402 is a universal CAR-T cell product targeting CD7 derived from healthy donors and intended for the treatment of T-ALL/LBL. It is genetically modified to avoid fratricide, graft-versus-host ...

"Jim has been instrumental in bringing more than 25 different therapeutics into the clinic, including multiple gene therapy and CAR-T assets. We remain diligently focused on the launch of our pivotal ...